Search research articles
Contact Us
Filters
Showing results (91-100 of 102) with videos related to
Page
of 11
Sort By:
Lupus
|
December 17, 2008
Sixth meeting of the European Forum on antiphospholipid antibodies. How to improve the understanding of the antiphospholipid syndrome?
Z Rotar, B Rozman, P G de Groot, et al.
Annals of the Rheumatic Diseases
|
December 8, 2007
Prevalence and clinical associations of anti-Ku antibodies in patients with systemic sclerosis: a European EUSTAR-initiated multi-centre case-control study
B Rozman, S Cucnik, S Sodin-Semrl, et al.
Lupus
|
May 29, 2012
Avidity of anti-β2-glycoprotein I antibodies in patients with antiphospholipid syndrome
S Čučnik, T Kveder, A Artenjak, et al.
Arthritis and Rheumatism
|
December 31, 1998
Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist
B Bresnihan, J M Alvaro-Gracia, M Cobby, et al.
Annals of the Rheumatic Diseases
|
April 15, 2004
EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis
C-S Yee, C Gordon, C Dostal, et al.
Annals of the Rheumatic Diseases
|
July 10, 2004
A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis
J van Holten, K Pavelka, J Vencovsky, et al.
Journal of Thrombosis and Haemostasis : JTH
|
August 22, 2009
The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study
B de Laat, V Pengo, I Pabinger, et al.
Lupus
|
March 13, 2001
Systemic lupus erythematosus. Disease outcome in patients with a disease duration of at least 10 years: second evaluation
A J Swaak, H G van den Brink, R J Smeenk, et al.
Rheumatology (Oxford, England)
|
February 7, 2001
Incomplete lupus erythematosus: results of a multicentre study under the supervision of the EULAR Standing Committee on International Clinical Studies Including Therapeutic Trials (ESCISIT)
A J Swaak, H van de Brink, R J Smeenk, et al.
Rheumatology (Oxford, England)
|
October 27, 1999
Systemic lupus erythematosus: clinical features in patients with a disease duration of over 10 years, first evaluation
A J Swaak, H G van den Brink, R J Smeenk, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 102) with videos related to
Sort By:
Page
of 11
Lupus
|
December 17, 2008
Sixth meeting of the European Forum on antiphospholipid antibodies. How to improve the understanding of the antiphospholipid syndrome?
Z Rotar, B Rozman, P G de Groot, et al.
Annals of the Rheumatic Diseases
|
December 8, 2007
Prevalence and clinical associations of anti-Ku antibodies in patients with systemic sclerosis: a European EUSTAR-initiated multi-centre case-control study
B Rozman, S Cucnik, S Sodin-Semrl, et al.
Lupus
|
May 29, 2012
Avidity of anti-β2-glycoprotein I antibodies in patients with antiphospholipid syndrome
S Čučnik, T Kveder, A Artenjak, et al.
Arthritis and Rheumatism
|
December 31, 1998
Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist
B Bresnihan, J M Alvaro-Gracia, M Cobby, et al.
Annals of the Rheumatic Diseases
|
April 15, 2004
EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis
C-S Yee, C Gordon, C Dostal, et al.
Annals of the Rheumatic Diseases
|
July 10, 2004
A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis
J van Holten, K Pavelka, J Vencovsky, et al.
Journal of Thrombosis and Haemostasis : JTH
|
August 22, 2009
The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study
B de Laat, V Pengo, I Pabinger, et al.
Lupus
|
March 13, 2001
Systemic lupus erythematosus. Disease outcome in patients with a disease duration of at least 10 years: second evaluation
A J Swaak, H G van den Brink, R J Smeenk, et al.
Rheumatology (Oxford, England)
|
February 7, 2001
Incomplete lupus erythematosus: results of a multicentre study under the supervision of the EULAR Standing Committee on International Clinical Studies Including Therapeutic Trials (ESCISIT)
A J Swaak, H van de Brink, R J Smeenk, et al.
Rheumatology (Oxford, England)
|
October 27, 1999
Systemic lupus erythematosus: clinical features in patients with a disease duration of over 10 years, first evaluation
A J Swaak, H G van den Brink, R J Smeenk, et al.
Page
of 11